Watanabe T, Dewey M J, Mintz B
Proc Natl Acad Sci U S A. 1978 Oct;75(10):5113-7. doi: 10.1073/pnas.75.10.5113.
The immediate purpose of the experiment was to establish a means of introducing specific mitochondrially encoded mutant genes into mice. Mouse teratocarcinoma stem cells were used as vehicles for the cytoplasmic markers because of their known capacity for normal somatic and germinal differentiation after injection into blastocysts. The mutation of choice, chloramphenicol resistance (CAP(R)), was first produced in a melanoma cell line by mutagenesis and selection. The CAP(R) trait was then transferred from a resistant melanoma cell to a sensitive (CAP(S)) teratocarcinoma cell by fusing to the latter only the cytoplasmic portion of the CAP(R) donor. This indirect route demonstrated the cytoplasmic provenance of the mutation. Protein synthesis in mitochondria isolated from the cybrid, or cytoplasmic hybrid, cells was barely affected by chloramphenicol, in contrast to the inhibitory influence of the drug on mitochondria of the parent teratocarcinoma line. Cells of the cybrid clone resembled teratocarcinoma cells and retained their ability to form diverse tissues in solid tumors produced from subcutaneous grafts. Cells from the tumors were retransplanted and were tested periodically by culture in chloramphenicol; they were found to be stably CAP(R) even after 16 weeks in vivo in the absence of the selective agent. The CAP(R) cybrids were microinjected into blastocysts of another inbred strain and, after transfer to foster mothers, mosaic mice were obtained. They comprised both cybrid- and blastocyst-derived cells in various tissues, as indicated by strain-specific nuclear markers. These results demonstrate successful normal differentiation of the CAP(R) lineage in vivo. Teratocarcinoma cybrids thus offer a practical portal of entry of preselected mitochondrial genes into mice. This will ultimately permit in vivo investigation of maternally transmitted traits, of mitochondrial genetic influences in specialized cells, and of possible roles of cytoplasmic genes in clinical and disease states.
该实验的直接目的是建立一种将特定线粒体编码突变基因导入小鼠的方法。小鼠畸胎瘤干细胞被用作细胞质标记物的载体,因为已知它们在注入囊胚后具有正常的体细胞和生殖细胞分化能力。所选择的突变是氯霉素抗性(CAP(R)),它首先通过诱变和筛选在黑色素瘤细胞系中产生。然后,通过仅将CAP(R)供体的细胞质部分与敏感(CAP(S))畸胎瘤细胞融合,将CAP(R)性状从抗性黑色素瘤细胞转移到敏感的畸胎瘤细胞。这条间接途径证明了突变的细胞质来源。与药物对亲代畸胎瘤细胞系线粒体的抑制作用相反,从胞质杂种细胞分离的线粒体中的蛋白质合成几乎不受氯霉素的影响。胞质杂种克隆的细胞类似于畸胎瘤细胞,并保留了它们在皮下移植产生的实体瘤中形成多种组织的能力。将肿瘤细胞重新移植,并通过在氯霉素中培养定期进行检测;即使在体内无选择剂的情况下培养16周后,发现它们仍稳定地具有CAP(R)抗性。将具有CAP(R)抗性的胞质杂种细胞显微注射到另一个近交系的囊胚中,转移到代孕母鼠后,获得了嵌合体小鼠。如菌株特异性核标记所示,它们在各种组织中同时包含胞质杂种来源和囊胚来源的细胞。这些结果证明了CAP(R)谱系在体内成功地正常分化。因此,畸胎瘤胞质杂种为预选的线粒体基因进入小鼠提供了一个实际的途径。这最终将允许对母系遗传性状、特殊细胞中线粒体遗传影响以及细胞质基因在临床和疾病状态中的可能作用进行体内研究。